Holen Sie sich die Stockscreener-App
8.50
0.59%
0.05
Handel nachbörslich:
8.63
0.13
+1.53%
Schlusskurs vom Vortag:
$8.45
Offen:
$8.31
24-Stunden-Volumen:
1.29M
Relative Volume:
1.15
Marktkapitalisierung:
$1.34B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-7.0833
EPS:
-1.2
Netto-Cashflow:
$-90.59M
1W Leistung:
-2.19%
1M Leistung:
-3.19%
6M Leistung:
+39.80%
1J Leistung:
+116.84%
1-Tages-Spanne:
$8.31
$8.62
1-Wochen-Bereich:
$8.15
$9.21
52-Wochen-Spanne:
$3.7599
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.50 | 1.34B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan
Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat
235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat
Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Keratoconus Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix - Barchart
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts - Inkl
Ocular Therapeutix announces over 300 subjects randomized in SOL-1 - Yahoo Finance
Ocular Pokes Ahead on Randomized Subjects - Baystreet.ca
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 - The Manila Times
Braidwell LP Has $19.49 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC's 10th Largest Position - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 29, 2024) - GuruFocus.com
Neuropathic Ocular Pain Market Is Booming Worldwide 2024-2031 | - openPR
Acuta Capital Partners LLC Cuts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 28, 2024) - GuruFocus.com
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock By Investing.com - Investing.com Canada
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com India
Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 By Investing.com - Investing.com Australia
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix chief scientific officer sells shares worth $26,561 - Investing.com
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Clinical Data at Major Healthcare Conferences in December - StockTitan
OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com
Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Hypertension Pipeline Forecast 2024: FDA Approvals, - openPR
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN
Ocular Therapeutix Q3 2024 Earnings Preview - MSN
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):